Literature DB >> 7706014

Cost-utility analysis of group living in dementia care.

A Wimo1, B Mattson, I Krakau, T Eriksson, A Nelvig, G Karlsson.   

Abstract

A cost-utility analysis (CUA) was applied to group living for dementia patients. A Markov-model of an expected life-length of 8 years was used. Forty-six patients in group living were compared to 39 patients living at home by inclusion and 23 institutionalized patients. When the cost per gained quality-adjusted life-year (QALY) was calculated, the group living alternative was the most favorable for the patients, giving a cost per paired QALY of US dollars < 0. In the extensive sensitivity analysis the main result was consistent but methodological problems were indicated.

Entities:  

Mesh:

Year:  1995        PMID: 7706014     DOI: 10.1017/s0266462300005250

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  8 in total

1.  Costs of Mini Mental State Examination-related cognitive impairment.

Authors:  L Jönsson; P Lindgren; A Wimo; B Jönsson; B Winblad
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 2.  The use of QALY and non-QALY measures of health-related quality of life. Assessing the state of the art.

Authors:  M Deverill; J Brazier; C Green; A Booth
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Authors:  Jaime Caro; Maribel Salas; Alexandra Ward; Denis Getsios; Kristen Migliaccio-Walle; Frances Garfield
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact.

Authors:  M D Walker; S S Salek; A J Bayer
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

Review 5.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

6.  Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

Authors:  Frances B Garfield; Denis Getsios; J Jaime Caro; Anders Wimo; Bengt Winblad
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care.

Authors:  Anders Wimo; Linus Jönsson; Laura Fratiglioni; Per Olof Sandman; Anders Gustavsson; Anders Sköldunger; Lennarth Johansson
Journal:  Alzheimers Res Ther       Date:  2016-11-18       Impact factor: 6.982

8.  Developing a dementia-specific preference--based quality of life measure (AD-5D) in Australia: a valuation study protocol.

Authors:  Tracy A Comans; Kim-Huong Nguyen; Brendan Mulhern; Megan Corlis; Li Li; Alyssa Welch; Susan E Kurrle; Donna Rowen; Wendy Moyle; Sanjeewa Kularatna; Julie Ratcliffe
Journal:  BMJ Open       Date:  2018-01-21       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.